BVCF — 2021 Investments

2 investments dated 2021 · listed companies and verified rows first · show all

Cellenkoscellenkosinc.comSeries A · Nov 2021 · $15M

Cellenkos is a clinical-stage biotechnology company developing allogeneic, tissue-targeted, cord blood-derived regulatory T cell (T-REG) therapies.

BiotechHealthtech

Oculisoculis.com inSeries C · May 2021 · $57M

Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments.

BiotechHealthtechMedical DevicesBoston, CH

Riad Sherif(Chief Executive Officer)in

Co-investorsBay City Capital Brunnur Ventures GP Pivotal Life Sciences VI Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.